OBJECTIVE: Severe energy restriction in the treatment of obesity is limited by catabolism of body protein stores and, consequently, loss of lean as well as fat tissue. Growth hormone (GH), whose secretion is markedly impaired in obesity, is endowed with both lipolytic and protein anabolic properties. The aim of this study was to verify the effects of GH administration on body composition, plasma leptin levels and energy metabolism in obese patients undergoing severe dietary restriction. DESIGN: Single-blind placebo-controlled study. Twenty obese women were fed a diet of 41.86 kJ/kg ideal body weight (IBW) daily for 4 weeks: 10 of them were randomly assigned to a 4 week treatment with biosynthetic GH (rhGH, Saizen, Serono, Rome, Italy), 1 U/kg IBW/week in daily subcutaneous injections; the other 10 patients, matched for age and BMI, received vehicle only. SUBJECTS: Twenty women with simple obesity (age: 25.4 AE 1.07 y, BMI: 35.9 AE 0.35 kg/m 2 ). MEASUREMENTS: Plasma IGF-I and leptin, serum markers of bone turnover (serum bone isoenzyme of alkaline phosphatase, osteocalcin and urinary hydroxyproline), nitrogen balance, body composition (by DEXA), and resting energy expenditure (REE, by indirect calorimetry) were evaluated at baseline and after 4 weeks. RESULTS: Mean IGF-I plasma levels, not in¯uenced by energy restriction in patients receiving placebo, displayed a signi®cant increase in the group treated with rhGH. The mean weight reduction and fat mass loss were not signi®cantly different in the two groups (6.0 AE 0.51 vs 7.2 AE 0.30 kg, NS, and 5.36 AE 0.460 vs 4.28 AE 0.572 kg, NS, with rhGH and placebo, respectively). Likewise, plasma leptin levels decreased signi®cantly in weight-reduced subjects receiving either rhGH (from 16.2 AE 2.37 to 6.4 AE 0.39 ng/ml, P`0.05) or placebo (from 14.3 AE 2.55 to 7.7 AE 3.77 ng/ml, P`0.05). On the contrary, the mean decrease of lean body mass (LBM) was signi®cantly lower in the GH-treated patients than in those receiving vehicle (1.52 AE 0.60 vs 3.79 AE 0.45 kg, P`0.05). In keeping with these ®ndings, the mean daily nitrogen balance was signi®cantly less negative in the GH-treated subjects than in the vehicle-injected patients (mean of the 4 week daily urine collections 7185.7 AE 40.33 vs 7363.9 AE 55.47 mmol/d, P`0.05, respectively). Further, a signi®cant reduction of mean REE was recorded in the energy-restricted placebo-treated patients (from 8807 AE 498 to 7580 AE 321 kJ/24 h, P`0.05), but not in the patients receiving rhGH (from 8367 AE 580 to 8903 AE 478 kJ/ 24 h, NS). Actually, when corrected for LBM, REE was even increased by GH administration (from 197.9 AE 11.76 to 219.3 AE 9.87 kJ/kg LBM/24 h, P`0.05), whereas it was unchanged in the placebo group (from 201.7 AE 13.85 to 190.0 AE 9.87 kJ/kg LBM/24 h, NS). A tendency of serum markers of bone turnover to increase was observed in the patients treated with rhGH, however with no changes in bone mineral content and density. CONCLUSION: rhGH treatment, though unable to enhance diet-induced weight and fat mass reduction, was effective in stimulating IGF-I production and conserving LBM and increasing its energy metabolism even in the presence of severe energy restriction.
Introduction
A major drawback of energy restriction for the treatment of obesity is represented by catabolism of body proteins and negative nitrogen balance. As a consequence, weight-reducing diets result in loss of lean as well as fat tissue. 1 Since protein-supplemented diets produce only a modest nitrogen sparing, 2 more effective tools are needed to preserve protein stores and lean body mass (LBM), which is the main determinant of resting energy expenditure (REE), 3 during dietary restriction.
Growth hormone (GH) is endowed with both lipolytic and protein anabolic properties. 4 ± 7 Its action is mostly mediated by insulin-like growth factor I (IGF-I), whose synthesis is greatly in¯uenced by the nutritional status. 8 In obesity spontaneous as well as pharmacologically triggered GH secretion is greatly impaired while peripheral levels of IGF-I are only inconstantly blunted. In a few trials, treatment with high-dose GH appeared effective, when compared to placebo, in conserving LBM in energy-restricted obese subjects, 9 ± 12 and in reducing body fat in obese women during a weight-maintaining diet. 13 In addition, GH administration to GH-de®cient adults is associated with an increase in REE, likely through the enhancement of peripheral conversion of thyroxine (T4) to triiodothyronine (T3). 14, 15 GH treatment was also found capable of increasing serum markers of bone turnover in normal volunteers 16 and GH-de®-cient adults 17 and, in the latter, bone mineral density in the long term. 17 A decrease in plasma leptin concentrations has been described in obese patients after diet-induced weight loss 18 and in GH-de®cient adults after GH substitution therapy. 19 The impact of the combination of GH treatment and energy restriction on peripheral leptin levels in obese patients is unknown.
The present study was aimed at evaluating the effects of GH treatment on weight loss, body composition and plasma leptin levels in a group of obese subjects undergoing severe dietary restriction. Another objective was to establish the in¯uence of severe hypocaloric diet, associated or not with GH administration, on circulating levels of IGF-I. Finally, we investigated the effects of GH administration on REE, glucose and lipid metabolism, bone turnover and bone mineral content (BMC) and density (BMD).
Methods

Subjects
Twenty obese women aged 25.4AE 1.0 7 (mean AE standard error) years with a body mass index (BMI, calculated as weight divided by height squared, kg/ m 2 ) of 35.9AE 0.35 gave their informed consent to participate in this study, which was approved by the Ethical Committee of our Institution. The subjects were in good general health and a medical evaluation including history, physical examination and routine blood chemistry revealed no abnormalities. Thyroid function was normal. None of the patients was taking any medications or exercising regularly during the 3 months preceding the study. During the same period of time, their body weight had been stable.
The subjects were studied as inpatients in our department. They were fed a balanced diet of 41.86 kJ/kg ideal body weight (IBW) daily for 4 weeks. Energy was supplied in a ratio of 50% carbohydrate (73.3 g), 30% fat (18.2 g) and 20% protein (27.9 g).
Care was exercised to maintain, during hospitalisation, the usual daily energy expenditure; this was accomplished by individual diary records and programs of physical activity.
According to a single-blind design, 10 patients were randomly assigned to a 4 week treatment with biosynthetic GH (rhGH, Saizen, Serono, Rome, Italy) 1 U/kg IBW/week in daily subcutaneous injections given at 8 pm. The other 10 patients, matched for age and BMI, received vehicle only.
Measurements
The subjects were weighed at the same time each morning before breakfast. Pulse rate and blood pressure were recorded daily. Circulating concentrations of glucose, insulin, free fatty acids (FFA), IGF-I, leptin, calcium, phosphate, bone isoenzyme of alkaline phosphatase (AP), osteocalcin, free thyroid hormones (fT4 and fT3), cholesterol and triglycerides were measured on blood samples collected after an overnight fast, under baseline conditions and at the end of the study. Twenty-four-hour urine samples were collected daily for nitrogen balance, and at baseline and after study completion for the estimation of calcium and hydroxyproline. Completeness of the collections was monitored by quantitating urinary creatinine excretion. 20 Urinary 24-h creatinine and urea nitrogen excretion were determined using autoanalyser modi®cations of published methods that measure both urea and ammonia nitrogen; 20, 21 24-h nitrogen balance was calculated by subtracting the urinary urea nitrogen plus 4 g nitrogen from the total nitrogen ingested. 22, 23 Serum concentrations of glucose, calcium, phosphate, AP, cholesterol and triglyceride were measured by routine assays. Serum insulin concentrations were estimated by¯uoro-enzymatic-immunoassay (FEIA) using a commercial kit (Tosoh, Tokyo, Japan); the normal range for insulin is 3.96±146.4 pmolal. Plasma concentrations of IGF-I were measured, after extraction with acid-ethanol, by RIA using a commercial kit (Nichols Institute Diagnostic, San Juan de Capistrano, CA, USA); the normal range for IGF-I is, for females aged 16±26 years, 182±780 ngaml. Plasma leptin was determined by RIA using a human leptin RIA kit (Linco Research, St. Charles, MO, USA). In our laboratory the mean value for plasma leptin obtained in 23 normal weight (BMI 23.6AE 0.57) age and sex matched blood donors was 6.8 AE 0.93 ng/ml. Serum osteocalcin was measured by RIA using a commercial kit (Cis Biointernational, Gif sur Yvette, France); the normal range is 10.7±24.7 ngaml. The assay of FFA was performed by an enzymatic method using reagents purchased from Boehringer Mannheim Yamanouchi (Tokyo, Japan); the FFA normal range is 250±270 mEqal. The urinary concentrations of calcium, phosphate and hydroxyproline were measured by colorimetric assays, Boehringer Mannheim (Germany) for the ®rst two parameters and by highperformance liquid chromatography (HPLC) for the third one. The normal ranges are 2.49±7.48 mmolad for urinary calcium, 12.91±32.29 mmolad for urinary phosphate and 76.26±305.0 mmoladam 2 for urinary hydroxyproline. The analysis of body composition for Growth hormone treatment in obesity M Tagliaferri et al the evaluation of fat mass, LBM, BMC and BMD was performed at the beginning and at the end of the 4th week of the study by dual energy X-ray absorptiometry (DEXA, Hologic QDR-1000, Waltham, MA, USA). LBM comprises both muscle tissue and non muscle fat-free tissue (including the water space), with the exclusion of BMC. BMC and BMD are expressed as subtotal values, i.e. whole body minus head. REE was assessed by indirect calorimetry, after an overnight fast and a 30 min bed rest; patients were studied under basal conditions and weekly during the treatment. A computerized open circuit system was employed to measure gas exchange across a 25 l canopy (Sensor Medics 2900, Yorba Linda, CA, USA). The values were expressed as kJ/24 h and, when REE was corrected for LBM, as kJ/kg LBM/24 h.
Statistical analysis
Data are expressed as mean AE standard error, unless stated otherwise. Statistical analysis was performed using the Wilcoxon and Mann-Whitney non-parametric tests, as appropriate. A P value less than 0.05 was considered statistically signi®cant.
Results
Mean IGF-I plasma concentrations were not in¯u-enced by energy restriction in patients receiving placebo (from 205.5AE 40.6 to 239.6AE 38.9 ng/ml, NS), whereas they displayed a signi®cant increase in the group tested with rhGH (from 240.7AE 21.8 to 319.4 AE 30.0 ng/ml, P`0.01).
The anthropometric parameters of all subjects are reported in Table 1 . The mean weight reduction and fat mass loss were not signi®cantly different in the two groups, although the GH-treated patients lost less weight and more fat mass than the placebo-treated patients (6.0AE 0.51 vs 7.2 AE 0.30 kg, NS, and 5.36AE 0.460 vs 4.28 AE 0.572 kg, NS, respectively). Plasma leptin concentrations were signi®cantly decreased in weight-reduced subjects following either GH or placebo administration (Table 2) . Like fat mass loss, leptin decrease was slightly greater in GH than in placebo-treated patients. On the contrary, the mean decrease of LBM was signi®cantly lower in the GHtreated patients than in those receiving vehicle (1.52 AE 0.60 vs 3.79AE 0.45 kg, P`0.05). During the 41.86 kJ/kg IBW diet, mean nitrogen balance was less negative in the GH-treated patients compared to the vehicle-injected women (mean of the 4 week daily urine collections 7185.7AE 40.3 vs 7363.9AE 55.4 mmol/d, P`0.05, respectively).
A signi®cant reduction of mean REE was observed in the energy-restricted placebo-treated patients (from 8807 AE 498.9 to 7580 AE 321.9 kJ/24 h, P`0.05), whereas the same parameter was not modi®ed in the patients receiving rhGH (from 8367 AE 580 to 8903 AE 478 kJ/24 h, NS). Actually, when corrected for LBM, REE was even increased by GH administration (from 197.9AE 11.76 to 219.3AE 9.87 kJ/kg LBM/24 h, P`0.05), whereas it was unchanged in the placebo group (from 201.7 AE 13.85 to 190.0AE 9.87 kJ/kg LBM/24 h, NS). Growth hormone treatment in obesity M Tagliaferri et al
As reported in Table 2 , a signi®cant decrease in total cholesterol and increase in FFA, of comparable magnitude in the two groups of patients, were observed. Serum triglycerides were substantially unchanged in both groups, and the same held true for glucose and thyroid hormones. Diet tended to reduce plasma insulin, although not reaching statistical signi®cance, in vehicle injected patients, but not in those receiving GH. Although no signi®cant changes in insulin concentrations were detected within each treatment group even when considering delta values, i.e. differences between baseline and ®nal concentrations (727AE 18.3 vs 7 AE 23.3 pmol/l, NS, in the placebo-and GH-treated patients, respectively), the absolute post-treatment insulin values were signi®-cantly different between the two groups (49 AE 6.6 vs 105AE 14.4 pmol/l, P`0.05, after placebo and after rhGH, respectively).
Serum AP bone isoenzyme increased signi®cantly in GH-treated patients, who also displayed a moderate rise in serum osteocalcin and urinary hydroxyproline ( Table 3) . None of these parameters was modi®ed in subjects receiving vehicle. While these latter showed a signi®cant decrease in urinary calcium, the same parameter was unchanged in GH-treated patients. No signi®cant changes in serum calcium and phosphate, as well as in subtotal BMC and BMD, were recorded in the two groups of obese patients along the study period.
Discussion
Nutritional status plays a central role in the regulation of IGF-I production and hence of most of the biological actions of GH. IGF-I plasma concentrations are low in malnourished patients 8 while, in normal subjects, fasting lowers plasma IGF-I levels under basal conditions 24 and in response to GH administration. 25 In obese subjects, the IGF-I production induced by exogenous GH is gradually impaired by the progressive limitation of energy intake. 9 ± 11 The present study has shown that a number of biological actions of GH, i.e. stimulation of IGF-I synthesis, sparing of body proteins, enhancement of bone turnover and REE, are maintained in obese patients in conditions of severe energy restriction. This ®nding is in line with the observation that in energy-restricted obese patients the administration of GH in increasing dosage results in a dose-dependent rise of plasma IGF-I levels. A signi®cant IGF-I increase after prolonged GH administration has been reported, under experimental conditions similar to ours, by Drent et al. 26 These authors, however, failed to demonstrate changes in body composition by bioimpedance analysis (BIA). In our patients the IGF-I increase following GH treatment was accompanied by evident metabolic effects, chie¯y by sparing of LBM estimated by DEXA. This ®nding is in keeping with the improvement of nitrogen balance observed in the present study and in other series of energy-restricted obese patients treated with GH, 9, 10, 12 and demonstrates that GH anabolic properties are retained even when energy intake is markedly reduced. The lack of changes in IGF-I levels observed in our energy restricted placebo-treated patients ®ts in well with the resistance of obese patients to dietary restriction in terms of IGF-I reduction. 8 In our patients, the combination of GH treatment and energy restriction induced a greater, though not statistically signi®cant, fat mass loss compared to diet alone. Accordingly, leptin was reduced to a slightly greater extent by GH (60.5%) than by placebo administration (46.2%), in agreement with the data reported in GH de®cient GH-treated adults. 19 This is consistent with the failure of GH treatment to signi®cantly enhance diet-induced fat loss in obese patients observed in other studies 9, 10, 12 with the exception of a recent one 27 in which the patients received an energy intake (62.79 kJ/kg IBW daily) 50% higher than the one adopted in our protocol. A more striking decrease in body fat, especially at visceral level, 28 is well documented in obese patients receiving GH while on a normocaloric diet. 13, 28, 29 The observation of a smaller LBM loss in GHtreated women in spite of no signi®cant differences in changes of body weight and fat mass between the two groups may not be in contradiction; in fact, statistically insigni®cant but not negligible variations in parameters of body composition may account for the apparent discrepancy of these results. The good correspondence between body weight loss estimated by Growth hormone treatment in obesity M Tagliaferri et al DEXA (sum of fat mass and LBM losses) and body weight estimated using a balance gives consistency to the data. GH treatment has been found to increase REE in adult patients with GH de®ciency. 15, 30, 31 In one study 15 the increase in REE was positively correlated with the increase in T3 serum levels, caused by the GH-induced peripheral conversion of T4 to T3 itself. A signi®cant increase in REE, recognizable even when REE was corrected for LBM and not correlated with thyroid hormone concentrations, was also observed in obese women treated with rhGH for ®ve weeks but not following a hypocaloric diet. 29 In the present experience, conducted in severely energyrestricted obese women, GH administration appeared able not only to prevent the diet-induced reduction of REE but also to signi®cantly increase the value of REE corrected for unit of LBM. The latter ®nding suggests that in the GH-treated patients the maintenance of a REE similar to the pre-diet value was due not only to the sparing of LBM, but to the enhancement of energy metabolism of LBM itself. These effects did not appear to be correlated with changes in thyroid hormone concentrations.
Since DEXA is unable to distinguish between muscle tissue and water, the possibility that the¯uid retentive action of GH has contributed to the smaller decrease in LBM observed in the patients treated with the hormone should be considered. However, the hypothesis of an actual preservation of muscle mass by GH treatment is supported by the less negative nitrogen balance observed in the treated patients and by the maintenance, in the same women, of baseline values of REE, whose main determinant is muscle tissue and not water. Furthermore, in experimental conditions similar to ours, the body water changes estimated by BIA were found to be not different between GH-and diet only-treated obese patients by Drent et al. 26 In our patients, the administration of rhGH did not affect the diet-induced modi®cations of serum lipid pro®le nor did it in¯uence serum glucose levels. However, the decrease in insulin levels seen in energy-restricted vehicle-injected patients was completely prevented by GH treatment in patients undergoing the same diet regimen. These ®ndings con®rm the GH-induced worsening of carbohydrate metabolism usually seen in both normal man 32 and GH de®cient subjects. 33 The relevance of GH in the physiology of bone remodelling is well recognized with the GH/IGF-I system promoting bone turnover, with a prevalence of formation over reabsorption and a positive net balance at each remodelling site. In fact, long-term administration of rhGH has been shown to signi®cantly improve bone mineralization in GH de®cient adults, 34 who display reduced BMD and increased risk for fracture. 35 In the present study, a tendency of the serum markers of bone turnover (AP bone isoenzyme, serum osteocalcin and urinary hydroxyproline) to increase was observed in obese patients treated with rhGH but not in energy-restricted placebo-treated patients. Moreover, rhGH treatment appeared to prevent, in our obese women, a diet-related reduction of urinary calcium. This might be due to the early activation of bone turnover induced by the hormone or to an enhanced intestinal calcium absorption secondary to increased vitamin D activation. In any case, no changes in subtotal BMC and BMD were recorded in the two groups of patients, possibly due to the short observation period.
In conclusion, rhGH treatment, if performed at adequate doses, appears to be effective in obese patients when associated with severely hypocaloric diets. The major bene®ts are represented by reduction of the LBM loss which follows energy restriction and improvement of LBM metabolic ef®ciency. These results encourage additional studies aimed at evaluating whether the administration of less expensive compounds capable of stimulating endogenous GH release is equally effective in improving the outcome of severe dietary restriction in obesity.
